DE60336581D1 - Verwendung von HPV16 und HPV18 VLPs als Vakzine gegen eine oder mehrere onkogene HPV des Typus 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68 - Google Patents

Verwendung von HPV16 und HPV18 VLPs als Vakzine gegen eine oder mehrere onkogene HPV des Typus 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68

Info

Publication number
DE60336581D1
DE60336581D1 DE60336581T DE60336581T DE60336581D1 DE 60336581 D1 DE60336581 D1 DE 60336581D1 DE 60336581 T DE60336581 T DE 60336581T DE 60336581 T DE60336581 T DE 60336581T DE 60336581 D1 DE60336581 D1 DE 60336581D1
Authority
DE
Germany
Prior art keywords
hpv16
types
vaccines against
oncogenic hpv
hpv18 vlps
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60336581T
Other languages
German (de)
English (en)
Inventor
Gary Dubin
Bruce Innis
Moncef M Slaoui
M A C Wettendorff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Application granted granted Critical
Publication of DE60336581D1 publication Critical patent/DE60336581D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE60336581T 2002-12-20 2003-12-18 Verwendung von HPV16 und HPV18 VLPs als Vakzine gegen eine oder mehrere onkogene HPV des Typus 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68 Expired - Lifetime DE60336581D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43503502P 2002-12-20 2002-12-20
US49665303P 2003-08-20 2003-08-20
PCT/EP2003/014562 WO2004056389A1 (en) 2002-12-20 2003-12-18 Hpv-16 and -18 l1 vlp vaccine

Publications (1)

Publication Number Publication Date
DE60336581D1 true DE60336581D1 (de) 2011-05-12

Family

ID=32685362

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60336581T Expired - Lifetime DE60336581D1 (de) 2002-12-20 2003-12-18 Verwendung von HPV16 und HPV18 VLPs als Vakzine gegen eine oder mehrere onkogene HPV des Typus 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68

Country Status (28)

Country Link
US (2) US20060251676A1 (https=)
EP (1) EP1572233B1 (https=)
JP (1) JP5475939B2 (https=)
KR (3) KR20050086924A (https=)
AP (1) AP2005003347A0 (https=)
AR (1) AR042530A1 (https=)
AT (1) ATE503492T1 (https=)
AU (1) AU2003293942B2 (https=)
BE (3) BE2015C068I2 (https=)
BR (1) BR0317544A (https=)
CA (1) CA2510457C (https=)
CY (1) CY1111552T1 (https=)
DE (1) DE60336581D1 (https=)
DK (1) DK1572233T3 (https=)
EA (2) EA200701633A1 (https=)
EC (1) ECSP055869A (https=)
IL (1) IL169085A (https=)
IS (1) IS2811B (https=)
MA (1) MA27581A1 (https=)
MX (1) MXPA05006764A (https=)
MY (1) MY144492A (https=)
NO (1) NO20052846L (https=)
NZ (1) NZ540811A (https=)
OA (1) OA13147A (https=)
PL (1) PL215257B1 (https=)
PT (1) PT1572233E (https=)
TW (1) TWI349557B (https=)
WO (1) WO2004056389A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100629028B1 (ko) * 1998-10-16 2006-09-26 글락소스미스클라인 바이오로지칼즈 에스.에이. 애쥬번트 시스템 및 백신
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
US7858098B2 (en) 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
JP2008502633A (ja) * 2004-06-16 2008-01-31 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Ｈｐｖ１６およびｈｐｖ１８ならびにｈｐｖ３１、４５または５２から選ばれる少なくとも１つの別のｈｐｖ型に対するワクチン
US7758866B2 (en) 2004-06-16 2010-07-20 Glaxosmithkline Biologicals, S.A. Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52
EP1877087B1 (en) 2005-04-15 2013-02-20 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen
AR053715A1 (es) * 2005-04-26 2007-05-16 Glaxosmithkline Biolog Sa Vacuna multivalente de vph
WO2006114312A2 (en) * 2005-04-26 2006-11-02 Glaxosmithkline Biologicals S.A. Vaccine
WO2008134935A1 (en) 2007-04-29 2008-11-13 Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Truncated human papillomavirus type 18 l1 proteins
US9428555B2 (en) 2007-04-29 2016-08-30 Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Truncated L1 protein of Human Papillomavirus type 16
DK2403507T3 (en) * 2009-03-05 2018-06-06 Jenny Colleen Mccloskey TREATMENT OF INFECTION
CN104288763B (zh) * 2009-06-19 2018-03-06 艾金株式会社 宫颈癌疫苗
US20170212116A1 (en) 2014-01-31 2017-07-27 Ulisse Biomed Srl Biosensors for the detection of infection and associated maladies
US10799574B2 (en) 2014-10-24 2020-10-13 Hpvvax. Llc Method and composition for treating cancer or skin lesion using a vaccine
CN107001430A (zh) 2014-10-24 2017-08-01 哈普威克斯有限责任公司 癌症和皮肤病变治疗
WO2016194685A1 (ja) * 2015-06-02 2016-12-08 テルモ株式会社 アルミニウムを含有するアジュバント組成物およびこれを含むワクチン組成物
KR20250136930A (ko) 2018-03-06 2025-09-16 프레시전 인코포레이티드 사람 파필로마바이러스 백신 및 이의 용도
IL277128B2 (en) 2018-03-06 2025-11-01 Precigen Inc Hepatitis b vaccines and uses of the same
WO2019233412A1 (zh) * 2018-06-04 2019-12-12 厦门大学 一种人乳头瘤病毒18型l1蛋白的突变体
WO2020117715A1 (en) 2018-12-03 2020-06-11 Board Of Regents, The University Of Texas System Oligo-benzamide analogs and their use in cancer treatment

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4332596A1 (de) * 1993-09-24 1995-03-30 Martin Josef Dr Sapp Monoklonale Antikörper
EP1015561B1 (en) 1997-09-05 2006-07-19 Medimmune, Inc. In vitro method for disassembly/reassembly of papillomavirus virus-like particles (vlps)
AU764138B2 (en) * 1999-02-05 2003-08-14 Merck Sharp & Dohme Corp. Human papilloma virus vaccine formulations
US6245568B1 (en) 1999-03-26 2001-06-12 Merck & Co., Inc. Human papilloma virus vaccine with disassembled and reassembled virus-like particles
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
US6908613B2 (en) * 2000-06-21 2005-06-21 Medimmune, Inc. Chimeric human papillomavirus (HPV) L1 molecules and uses therefor
NZ523408A (en) * 2000-06-26 2006-02-24 Stressgen Biotechnologies Corp Human papilloma virus treatment

Also Published As

Publication number Publication date
ATE503492T1 (de) 2011-04-15
US20060251676A1 (en) 2006-11-09
BR0317544A (pt) 2005-11-22
KR20050086924A (ko) 2005-08-30
KR20120118087A (ko) 2012-10-25
CY1111552T1 (el) 2015-08-05
IS7885A (is) 2005-06-09
EP1572233A1 (en) 2005-09-14
TW200423957A (en) 2004-11-16
IL169085A0 (en) 2007-07-04
TWI349557B (en) 2011-10-01
OA13147A (en) 2006-12-13
HK1085378A1 (en) 2006-08-25
DK1572233T3 (da) 2011-06-27
PT1572233E (pt) 2011-06-07
AP2005003347A0 (en) 2005-06-30
AR042530A1 (es) 2005-06-22
BE2015C069I2 (https=) 2024-08-08
KR20120123616A (ko) 2012-11-08
KR101361769B1 (ko) 2014-02-10
AU2003293942B2 (en) 2009-12-10
WO2004056389A1 (en) 2004-07-08
BE2015C067I2 (https=) 2024-08-08
IL169085A (en) 2014-04-30
CA2510457A1 (en) 2004-07-08
EA200701633A1 (ru) 2007-12-28
NZ540811A (en) 2007-03-30
JP2006512413A (ja) 2006-04-13
ECSP055869A (es) 2005-09-20
EA009179B1 (ru) 2007-12-28
AU2003293942A1 (en) 2004-07-14
CA2510457C (en) 2011-12-06
BE2015C068I2 (https=) 2024-08-08
JP5475939B2 (ja) 2014-04-16
EP1572233B1 (en) 2011-03-30
IS2811B (is) 2012-11-15
MY144492A (en) 2011-09-30
MA27581A1 (fr) 2005-10-03
PL377710A1 (pl) 2006-02-06
US20050287161A1 (en) 2005-12-29
PL215257B1 (pl) 2013-11-29
NO20052846L (no) 2005-07-13
MXPA05006764A (es) 2005-09-08
EA200500834A1 (ru) 2006-02-24

Similar Documents

Publication Publication Date Title
DE60336581D1 (de) Verwendung von HPV16 und HPV18 VLPs als Vakzine gegen eine oder mehrere onkogene HPV des Typus 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68
AP1872A (en) Virus-like particles of human papillomavirus.
NO2012016I1 (no) Kombinasjon av HPV16 og HPV18 L1 viruslignende partikler
EP1660678A4 (en) MUTANT ADENO-ASSOCIATED VIRUS VIRUSES AND METHOD OF USE THEREOF
DE60027440D1 (de) Impfstoff gegen hbv und hpv
ATE471148T1 (de) Medizinische verwendung eines tetrahydrotriazoloä4,3-aüpyrazins
LTPA2015049I1 (lt) Žpv 45 l1 optimizuota ekspresija mielėse
CY1113875T1 (el) Βελτιστοποιημενη εκφραση hpv 58 l1 σε ζυμομυκητα
HUS1500061I1 (hu) A HPV16 és HPV18 és a HPV 31, 45 vagy 52 közül legalább egy másik HPV típus elleni vakcina
ATE358129T1 (de) 1,2,3,4,7,8-hexahydro-6h-c1,4)diazepinoc6,7,1- 1j)chinolinderivative als antipsychotika und mittel gegen obesitas
NO20044398L (no) Fotokatalysatorer inneholdende titanoksyd, samt fremgangsmate og anvendelse derav
DE50210920D1 (de) Verwendung von Aluminiumchlorohydrat in Deodoranten und Antiperspiranten
DE602004014604D1 (de) Herstellung und verwendung von mehrkarbidmaterialien
NO20055750L (no) Nye kjemiske forbindelser
SI1572233T1 (sl) Uporaba HPV16 in HPV18 kot cepivo proti enemu ali več onkogenih HPV tipa 31,33,35,39,45,51,52,56,58,59,66,68
IL179138A0 (en) Vaccine against hpv16 and hpv18 and at least another hpv type selected from hpv 31,45, or 52
DE60202679D1 (de) 4-(phenylpiperidin-4-ylidenmethyl) benzamidderivate und deren verwendung zur behandlung von schmerzen, angst oder gastrointestinalen störungen
DE502004012110D1 (de) 2-(3-phenyl-2-piperazinyl-3,4-dihydrochinazolin-4-yl) essigsäuren als antivirale mittel, speziell gegen cytomegalieviren
EP1322761A4 (en) HUMANIZED ANTIBODY AGAINST THE HEPATITE B VIRUS SURFACE ANTIGEN AND METHOD OF PREPARING THE SAME
DE60037263D1 (de) Virus-ähnliche Partikel, ihre Herstellung und ihre Verwendung beim pharmazeutischen Screening und funktionelle Genomanwendungen
DE60237181D1 (de) Kosmetische Zusammensetzung und Methode um farbentwickelnde Zubereitungen in Kosmetika zu benutzen
FI20020375A7 (fi) Menetelmä viruksen kaltaisten partikkeleiden (VKP) tuottamiseksi, plasmidikonstrukti sekä menetelmän käytöt
CY2015048I2 (el) Εμβολιο εναντι hpv16 και hpv18 και τουλαχιστον ενος αλλου τυπου hpv ο οποιος επιλεγεται απο hpv 31,45 ή 52
DE60336275D1 (de) Verfahren zur Herstellung von 3-(1,3-Dihydroimidazol-2-thion-1-yl)-chromanen und thiochromanen als Dopamin-beta-hydroxylase Inhibitor
Chi Prospectives of research institute of healthcare policy, Korean Medical Association